Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1940-1953

  Buhtoiarov, Ilia N ^a,b   Rakhmilevich, Alexander L ^a,b   Lanier, Lewis L ^c   Ranheim, Erik A ^a,b   Sondel, Paul M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD18 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; NITRIC OXIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; KLRK1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CONTACT; CELL INTERACTION; CELL STRAIN 3T3; CONTROLLED STUDY; CYTOSTASIS; DAUDI CELL; DBA MOUSE; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; LEUKEMIA CELL LINE; LEUKEMIA L 5178 Y; MACROPHAGE ACTIVATION; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; T CELL LYMPHOMA; UPREGULATION; ANIMAL; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOMA; MACROPHAGE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD18; ANTIGENS, CD40; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOPHENOTYPING; LYMPHOMA; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTOR CROSS-TALK;

EID: 61449149440     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0800443     Document Type: Article

References (51)

1. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
2. Chang, C. C., and S. Ferrone. 2006. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin. Cancer Biol. 16: 383-392.
3. Lamagna, C., M. Aurrand-Lions, and B. A. Imhof. 2006. Dual role of macrophages in tumor growth and angiogenesis. J. Leukocyte Biol. 80: 705-713.
4. Greeneltch, K. M., M. Schneider, S. M. Steinberg, D. J. Liewehr, T. J. Stewart, K. Liu, and S. I. Abrams. 2007. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res. 67: 10406-10416.
5. Bottino, C., R. Castriconi, L. Moretta, and A. Moretta. 2005. Cellular ligands of activating NK receptors. Trends Immunol. 26: 221-226.
6. Coudert, J. D., and W. Held. 2006. The role of the NKG2D receptor for tumor immunity. Semin. Cancer Biol. 16: 333-343.
7. Hayakawa, Y., and M. J. Smyth. 2006. Innate immune recognition and suppression of tumors. Adv. Cancer Res. 95: 293-322.
8. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526.
9. Liao, N. S., M. Bix, M. Zijlstra, R. Jaenisch, and D. Raulet. 1991. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 253: 199-202.
10. Diefenbach, A., J. K. Hsia, M. Y. Hsiung, and D. H. Raulet. 2003. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33: 381-391.
11. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
12. Větvicka, V., M. Hanikýrová, J. Vě tvicková, and G. D. Ross. 1999. Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules. Clin. Exp. Immunol. 115: 229-235.
13. Girart, M. V., M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner. 2007. Engagement of TLR3, TLR7, and NKG2D regulate IFN-γ secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J. Immunol. 179: 3472-3479.
14. Bertschmann, M., D. Käsermann, and R. Keller. 1990. MHC class-I antigen deficiency, malignancy and susceptibility of P815 mastocytoma to NK and macrophage killing. Int. J. Cancer 46: 739-744.
15. b) mice. Microbiol. Immunol. 51: 297-306.
16. Cerwenka. A., and L. L. Lanier. 2003. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61: 335-343.
17. Diefenbach, A., A. M. Jamieson, S. D. Liu, N. Shastri, and D. H. Raulet. 2000. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1: 119-126.
18. Strassmann, G., T. A. Springer, S. D. Somers, and D. O. Adams. 1986. Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen. J. Immunol. 136: 4328-4333.
19. Singh, R. A., and A. Sodhi. 1998. LFA-1-dependent tumoricidal activity of cisplatin-treated macrophages. Immunol. Cell Biol. 76: 343-349.
20. Buhtoiarov, I. N., H. D. Lum, G. Berke, D. M. Paulnock, P. M. Sondel, and A. L. Rakhmilevich. 2005. CD40 ligation activates murine macrophages via an IFN-γ-dependent mechanism resulting in tumor cell destruction in vitro. J. Immunol. 174: 6013-6022.
21. Buhtoiarov, I. N., H. D. Lum, G. Berke, P. M. Sondel, and A. L. Rakhmilevich. 2006. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 176: 309-318.
22. McGarrity, G. J., T. Steiner, and V. Vanaman. Detection of mycoplasmal infection of cell cultures by DNA fluorochrome staining. In Methods in Mycoplasmology: Diagnostic Mycoplasmology, Vol 2. J. G. Tully and S. Razin, eds. New York, Academic, 1983.
23. Matsuno, R., Y. Aramaki, H. Arima, Y. Adachi, N. Ohno, T. Yadomae, and S. Tsuchiya. 1998. Contribution of CR3 to nitric oxide production from macrophages stimulated with high-dose of LPS. Biochem. Biophys. Res. Commun. 244: 115-119.
24. Varma, T. K., C. Y. Lin, T. E. Toliver-Kinsky, and E. R. Sherwood. 2002. Endotoxin-induced γ interferon production: contributing cell types and key regulatory factors. Clin. Diagn. Lab. Immunol. 9: 530-543.
25. Hino, A., O. Igarashi, Y. I. Tagawa, Y. Iwakura, and H. Nariuchi. 2000. Interferon γ priming is not critical for IL-12 production of murine spleen cells. Cytokine 12: 12-20.
26. Hochrein, H., K. Shortman, D. Vremec, B. Scott, P. Hertzog, and M. O'Keeffe. 2001. Differential production of IL-12, IFN-α, and IFN-γ by mouse dendritic cell subsets. J. Immunol. 166: 5448-5455.
27. Hitoshi, Y., S. Mita, A. Tominaga, Y. Kikuchi, E. Sonoda, K. Takatsu, and Y. Watanabe. 1989. Interferon-γ inhibits the proliferation but not the differentiation of murine B cells in response to IL-5. Int. Immunol. 1: 185-190.
28. Yang, G., F. D. Coffman, and E. F. Wheelock. 1994. Characterization and purification of a macrophage-triggering factor produced in Mycoplasma arginini-infected L5178Y cell cultures. J. Immunol. 153: 2579-2591.
29. Ribeiro-Dias, F., M. Russo, J. A. Marzagão Barbuto, F. R. Fernandes do Nascimento, J. Timenetsky, and S. Jancar. 1999. Mycoplasma arginini enhances cytotoxicity of thioglycollate-elicited murine macrophages toward YAC-1 tumor cells through production of NO. J. Leukocyte Biol. 65: 808-814.
30. Uchimura, E., N. Watanabe, and Y. Kobayashi. 1997. Modulation by lipopolysaccharide of inflammatory cytokine production by two T cell lines. Cytokine 9: 727-733.
31. Bui, J. D., L. N. Carayannopoulos, L. L. Lanier, W. M. Yokoyama, and R. D. Schreiber. 2006. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors. J. Immunol. 176: 905-913.
32. Lodoen, M. B., G. Abenes, S. Umamoto, J. P. Houchins, F. Liu, and L. L. Lanier. 2004. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J. Exp. Med. 200: 1075-1081.
33. Neal, Z. C., M. Imboden, A. L. Rakhmilevich, K. M. Kim, J. A. Hank, J. Surfus, J. R. Dixon, H. N. Lode, R. A. Reisfeld, S. D. Gillies, and P. M. Sondel. 2004. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol. Immunother. 53: 41-52.
34. Rakhmilevich, A. L., I. N. Buhtoiarov, M. Malkovsky, and P. M. Sondel. 2008. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol. Immunother. 57: 1151-1160.
35. Diefenbach, A., J. K. Hsia, M. Y. Hsiung, and D. H. Raulet. 2003. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. Eur. J. Immunol. 33: 381-391.
36. Kato, T., R. Hakamada, H. Yamane, and H. Nariuchi. 1996. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. 156: 3932-3938.
37. Yamane, H., T. Kato, and H. Nariuchi. 1999. Effective stimulation for IL-12 p35 mRNA accumulation and bioactive IL-12 production of antigen-presenting cells interacted with Th cells. J. Immunol. 162: 6433-6441.
38. Kennedy, M. K., K. S. Picha, W. C. Fanslow, K. H. Grabstein, M. R. Alderson, K. N. Clifford, W. A. Chin, and K. M. Mohler. 1996. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26: 370-378.
39. Shi, C., X. Zhang, Z. Chen, M. K. Robinson, and D. I. Simon. 2001. Leukocyte integrin Mac-1 recruits Toll/interleukin-1 receptor superfamily signaling intermediates to modulate NF-κB activity. Circ. Res. 89: 859-865.
40. Lum, H. D., I. N. Buhtoiarov, G. Berke, D. M. Paulnock, P. M. Sondel, and A. L. Rakhmilevich. 2006. In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages. J. Leukocyte Biol. 79: 1181-1192.
41. Weinhold, K. J., L. T. Goldstein, and E. F. Wheelock. 1979. The tumor dormant state: quantitation of L5178Y cells and host immune responses during the establishment and course of dormancy in syngeneic DBA/2 mice. J. Exp. Med. 149: 732-744.
42. Wheelock, E. F., M. K. Robinson, and G. A. Truitt. 1982. Establishment and control of the L5178Y-cell tumor dormant state in DBA/2 mice. Cancer Metastasis Rev. 1: 29-44.
43. Chen, L. P., Y. Suzuki, C. M. Liu, and E. F. Wheelock. 1990. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: dependence of interleukin 2 on induced interferon-γ and on tumor necrosis factor for its antitumor effects. Cancer Res. 50: 1368-1374.
44. Liu, C. M., Y. Suzuki, L. P. Chen, T. Okayasu, C. E. Calkins, and E. F. Wheelock. 1990. Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects. Cancer Res. 50: 1361-1367.
45. Anikhovskaya, I., O. Oparina, M. Yakovleva, and M. Yakovlev. 2006. Intestinal endotoxin as a universal factor of adaptation and pathogenesis of general adaptation syndrome. Hum. Physiol. 32: 200-203.
46. Storz, M., K. Zepter, J. Kamarashev, R. Dummer, G. Burg, and A. C. Häffner. 2001. Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides). Cancer Res. 61: 452-454.
47. Carbone, A., A. Gloghini, V. Zagonel, D. Aldinucci, V. Gattei, M. Degan, S. Improta, R. Sorio, S. Monfardini, and A. Pinto. 1995. The expression of CD26 and CD40 ligand is mutually exclusive in human T-cell non-Hodgkin's lymphomas/leukemias. Blood 86: 4617-4626.
48. + T-cell non-Hodgkin's lymphoma. Blood 84: 866-782.
49. Voorzanger-Rousselot, N., and J. Y. Blay. 2004. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk. Lymphoma 45: 1239-1245.
50. Cantaluppi, V., M. C. Deregibus, L. Biancone, I. Deambrosis, B. Bussolati, A. Albini, and G. Camussi. 2006. The expression of CD154 by Kaposi's sarcoma cells mediates the anti-apoptotic and migratory effects of HIV-1-TAT protein. Int. J. Immunopathol. Pharmacol. 19: 81-96.
51. Bussolati, B., S. Russo, I. Deambrosis, V. Cantaluppi, A. Volpe, U. Ferrando, and G. Camussi. 2002. Expression of CD154 on renal cell carcinomas and effect on cell proliferation, motility and platelet-activating factor synthesis. Int. J. Cancer. 100: 654-661.